Clinical Trial: A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07623616) titled 'A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia' on April 08.

Brief Summary: This is the first study to administer ziftomenib to Japanese patients. In this study, the efficacy, safety, and pharmacokinetics of ziftomenib will be evaluated in patients with relapsed or refractory NPM1-mutated acute myeloid leukemia

Study Start Date: April 23

Study Type: INTERVENTIONAL

Condition: Acute Myeloid Leukemia (AML)

Intervention: DRUG: ziftomenib

Oral adminitration once daily

Recruitment Status: RECRUITING

Sponsor: Kyowa Kirin Co., Ltd.

Published by HT Digital Content S...